Dermatitis News

As the world faces the COVID-19 pandemic, wearing a mask or facial covering has been touted as one way to combat the spread of the virus. Most public places, such as grocery stores and essential locations, have now mandated customers and visitors must cover their mouth and nose. Meanwhile, health care providers and those who work in health care facilities have to wear full personal protective equipment, including a mask, for the duration of their shift.

Patients with cutaneous immune-mediated diseases, such as psoriasis, atopic dermatitis and hidradenitis suppurativa, may not have an increased risk for developing severe COVID-19, based on available data from the current and previous coronavirus outbreaks.

Leo Pharma, Oneness Biotech and Microbio Shanghai have entered into a worldwide exclusive licensing agreement for FB825, a novel atopic dermatitis and allergic asthma drug candidate, according to a press release.

Patients with both pruritus and chronic kidney disease stages 3 to 5 experienced reduced itch intensity at 12 weeks after treatment with oral difelikefalin compared with placebo, according to phase 2 trial results presented at the virtual National Kidney Foundation Spring Clinical Meetings.

Health care delivery is facing rapid changes and urgent issues in the wake of the COVID-19 outbreak, propelling the need for more proactive safety measures along with wider usage of telemedicine platforms, according to a letter published in Journal of the American Academy of Dermatology.

The phase 3 JADE COMPARE trial met its co-primary efficacy endpoints in adults with moderate to severe atopic dermatitis. Results from the trial, which compared the use of the JAK1 inhibitor abrocitinib with placebo, will be submitted for presentation at a future conference, according to a press release from Pfizer.

The novel interleukin 13 inhibitor lebrikizumab improved skin lesions, pruritis and quality of life among adults with moderate to severe atopic dermatitis, according to data from a phase 2b trial published in JAMA Dermatology.

A meta-analysis of efficacy and safety findings for atopic dermatitis showed that comparing therapeutic options was difficult due to differing study methodologies and a lack of head-to-head trials.

Eli Lilly and Company and Incyte announced that baricitinib met its primary endpoint in the BREEZE-AD4 and BREEZE-AD5 studies in patients with moderate to severe atopic dermatitis, according to two press releases.

KOLOA, Hawaii — At Hawaiian Eye 2020, Ashley Brissette, MD, MSc, discusses a case in which a patient presented with chronic allergic conjunctivitis that was not responding to traditional treatments. She found that the patient was on dupilumab for eczema, and the conjunctivitis was a side effect from the drug. She recommends an aggressive treatment regimen to treat the conjunctivitis.